| Year |
Citation |
Score |
| 2023 |
Thomas S, Hammell DC, Hassan HE, Stinchcomb AL. In Vitro-In Vivo Correlation of Buprenorphine Transdermal Systems Under Normal and Elevated Skin Temperature. Pharmaceutical Research. PMID 37095369 DOI: 10.1007/s11095-023-03487-z |
0.654 |
|
| 2022 |
Zambrana PN, Hou P, Hammell DC, Li T, Stinchcomb AL. Understanding Formulation and Temperature Effects on Dermal Transport Kinetics by IVPT and Multiphysics Simulation. Pharmaceutical Research. 39: 893-905. PMID 35578064 DOI: 10.1007/s11095-022-03283-1 |
0.349 |
|
| 2022 |
Shukla S, Bunge AL, Hassan HE, Stinchcomb AL. Investigator Impact on Reproducibility of Drug Bioavailability in Stratum Corneum Sampling by Tape Stripping. Pharmaceutical Research. PMID 35411510 DOI: 10.1007/s11095-022-03199-w |
0.699 |
|
| 2021 |
Shin SH, Yu M, Hammell DC, Ghosh P, Raney SG, Hassan HE, Stinchcomb AL. Evaluation of in vitro/in vivo correlations for three fentanyl transdermal delivery systems using in vitro skin permeation testing and human pharmacokinetic studies under the influence of transient heat application. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 34838928 DOI: 10.1016/j.jconrel.2021.11.030 |
0.824 |
|
| 2020 |
Shin SH, Rantou E, Raney SG, Ghosh P, Hassan H, Stinchcomb A. Cutaneous Pharmacokinetics of Acyclovir Cream 5% Products: Evaluating Bioequivalence with an In Vitro Permeation Test and an Adaptation of Scaled Average Bioequivalence. Pharmaceutical Research. 37: 210. PMID 33001286 DOI: 10.1007/s11095-020-02821-z |
0.796 |
|
| 2020 |
Thomas S, Shin SH, Hammell DC, Hassan HE, Stinchcomb AL. Effect of Controlled Heat Application on Topical Diclofenac Formulations Evaluated by In Vitro Permeation Tests (IVPT) Using Porcine and Human Skin. Pharmaceutical Research. 37: 49. PMID 32034502 DOI: 10.1007/S11095-019-2741-1 |
0.752 |
|
| 2018 |
Shin SH, Srivilai J, Ibrahim SA, Strasinger C, Hammell DC, Hassan HE, Stinchcomb AL. The Sensitivity of In Vitro Permeation Tests to Chemical Penetration Enhancer Concentration Changes in Fentanyl Transdermal Delivery Systems. Aaps Pharmscitech. PMID 30084070 DOI: 10.1208/S12249-018-1130-0 |
0.833 |
|
| 2018 |
Gonzalez-Cuevas G, Martin-Fardon R, Kerr TM, Stouffer DG, Parsons LH, Hammell DC, Banks SL, Stinchcomb AL, Weiss F. Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 29686308 DOI: 10.1038/S41386-018-0050-8 |
0.744 |
|
| 2017 |
Shin SH, Thomas S, Raney SG, Ghosh P, Hammell DC, El-Kamary SS, Chen WH, Billington MM, Hassan HE, Stinchcomb AL. In vitro-in vivo correlations for nicotine transdermal delivery systems evaluated by both in vitro skin permeation (IVPT) and in vivo serum pharmacokinetics under the influence of transient heat application. Journal of Controlled Release : Official Journal of the Controlled Release Society. 270: 76-88. PMID 29175139 DOI: 10.1016/J.Jconrel.2017.11.034 |
0.81 |
|
| 2017 |
Yu M, Abdallah IA, Shin SH, Hammell DC, Stinchcomb AL, Hassan HE. LC-MS determination of fentanyl in human serum and application to a fentanyl transdermal delivery pharmacokinetic study. Bioanalysis. PMID 28914084 DOI: 10.4155/Bio-2017-0174 |
0.702 |
|
| 2017 |
Shin SH, Ghosh P, Newman B, Hammell DC, Raney SG, Hassan HE, Stinchcomb AL. On the Road to Development of an in Vitro Permeation Test (IVPT) Model to Compare Heat Effects on Transdermal Delivery Systems: Exploratory Studies with Nicotine and Fentanyl. Pharmaceutical Research. PMID 28608140 DOI: 10.1007/S11095-017-2189-0 |
0.836 |
|
| 2017 |
Andar AU, Karan R, Pecher WT, DasSarma P, Hedrich WD, Stinchcomb AL, DasSarma S. Microneedle-Assisted Skin Permeation by Non-toxic Bioengineerable Gas Vesicle Nanoparticles. Molecular Pharmaceutics. PMID 28068767 DOI: 10.1021/Acs.Molpharmaceut.6B00859 |
0.404 |
|
| 2016 |
Abdallah IA, Hammell DC, Stinchcomb AL, Hassan HE. A fully validated LC-MS/MS method for simultaneous determination of nicotine and its metabolite cotinine in human serum and its application to a pharmacokinetic study after using nicotine transdermal delivery systems with standard heat application in adult smokers. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1020: 67-77. PMID 27023159 DOI: 10.1016/J.Jchromb.2016.03.020 |
0.587 |
|
| 2016 |
Abdallah IA, Hammell DC, Hassan HE, Stinchcomb AL. Norelgestromin/ethinyl estradiol intravenous infusion formulation optimization, stability and compatibility testing: A case study to overcome polysorbate 80 interference in chromatographic analysis. Journal of Pharmaceutical and Biomedical Analysis. 125: 145-53. PMID 27018506 DOI: 10.1016/J.Jpba.2016.03.024 |
0.642 |
|
| 2015 |
Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, Westlund KN. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. European Journal of Pain (London, England). PMID 26517407 DOI: 10.1002/Ejp.818 |
0.335 |
|
| 2014 |
Eldridge JA, Milewski M, Stinchcomb AL, Crooks PA. Synthesis and in vitro stability of amino acid prodrugs of 6-β-naltrexol for microneedle-enhanced transdermal delivery. Bioorganic & Medicinal Chemistry Letters. 24: 5212-5. PMID 25442314 DOI: 10.1016/J.Bmcl.2014.09.072 |
0.72 |
|
| 2014 |
Strasinger C, Paudel KS, Wu J, Hammell D, Pinninti RR, Hinds BJ, Stinchcomb A. Programmable transdermal clonidine delivery through voltage-gated carbon nanotube membranes Journal of Pharmaceutical Sciences. 103: 1829-1838. PMID 24788096 DOI: 10.1002/Jps.23940 |
0.808 |
|
| 2014 |
Ghosh P, Brogden NK, Stinchcomb AL. Fluvastatin as a micropore lifetime enhancer for sustained delivery across microneedle-treated skin. Journal of Pharmaceutical Sciences. 103: 652-60. PMID 24395718 DOI: 10.1002/Jps.23844 |
0.853 |
|
| 2014 |
Ghosh P, Lee D, Kim KB, Stinchcomb AL. Optimization of naltrexone diclofenac codrugs for sustained drug delivery across microneedle-treated skin. Pharmaceutical Research. 31: 148-59. PMID 23943543 DOI: 10.1007/s11095-013-1147-8 |
0.697 |
|
| 2013 |
Milewski M, Paudel KS, Brogden NK, Ghosh P, Banks SL, Hammell DC, Stinchcomb AL. Microneedle-assisted percutaneous delivery of naltrexone hydrochloride in yucatan minipig: in vitro-in vivo correlation. Molecular Pharmaceutics. 10: 3745-57. PMID 24053426 DOI: 10.1021/Mp400227E |
0.794 |
|
| 2013 |
Brogden NK, Banks SL, Crofford LJ, Stinchcomb AL. Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans. Pharmaceutical Research. 30: 1947-55. PMID 23761054 DOI: 10.1007/S11095-013-1036-1 |
0.834 |
|
| 2013 |
Ghosh P, Brogden NK, Stinchcomb AL. Effect of formulation pH on transport of naltrexone species and pore closure in microneedle-enhanced transdermal drug delivery. Molecular Pharmaceutics. 10: 2331-9. PMID 23590208 DOI: 10.1021/Mp3007083 |
0.821 |
|
| 2013 |
Brogden NK, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. Development of in vivo impedance spectroscopy techniques for measurement of micropore formation following microneedle insertion. Journal of Pharmaceutical Sciences. 102: 1948-56. PMID 23589356 DOI: 10.1002/Jps.23544 |
0.804 |
|
| 2013 |
Ghosh P, Pinninti RR, Hammell DC, Paudel KS, Stinchcomb AL. Development of a codrug approach for sustained drug delivery across microneedle-treated skin. Journal of Pharmaceutical Sciences. 102: 1458-67. PMID 23417751 DOI: 10.1002/Jps.23469 |
0.758 |
|
| 2012 |
Brogden NK, Milewski M, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. Diclofenac delays micropore closure following microneedle treatment in human subjects. Journal of Controlled Release : Official Journal of the Controlled Release Society. 163: 220-9. PMID 22929967 DOI: 10.1016/J.Jconrel.2012.08.015 |
0.839 |
|
| 2012 |
Paudel KS, Wu J, Hinds BJ, Stinchcomb AL. Programmable transdermal delivery of nicotine in hairless guinea pigs using carbon nanotube membrane pumps Journal of Pharmaceutical Sciences. 101: 3823-3832. PMID 22806243 DOI: 10.1002/Jps.23240 |
0.31 |
|
| 2012 |
Milewski M, Stinchcomb AL. Estimation of maximum transdermal flux of nonionized xenobiotics from basic physicochemical determinants. Molecular Pharmaceutics. 9: 2111-20. PMID 22702370 DOI: 10.1021/Mp300146M |
0.765 |
|
| 2012 |
Milewski M, Pinninti RR, Stinchcomb AL. Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin. Journal of Pharmaceutical Sciences. 101: 2777-86. PMID 22628183 DOI: 10.1002/Jps.23189 |
0.832 |
|
| 2011 |
Banks SL, Paudel KS, Brogden NK, Loftin CD, Stinchcomb AL. Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin. Pharmaceutical Research. 28: 1211-9. PMID 21301935 DOI: 10.1007/S11095-011-0372-2 |
0.823 |
|
| 2011 |
Milewski M, Stinchcomb AL. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride. Pharmaceutical Research. 28: 124-34. PMID 20577787 DOI: 10.1007/S11095-010-0191-X |
0.797 |
|
| 2010 |
Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and opportunities in dermal/transdermal delivery. Therapeutic Delivery. 1: 109-31. PMID 21132122 DOI: 10.4155/Tde.10.16 |
0.782 |
|
| 2010 |
Milewski M, Yerramreddy TR, Ghosh P, Crooks PA, Stinchcomb AL. In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin. Journal of Controlled Release : Official Journal of the Controlled Release Society. 146: 37-44. PMID 20678989 DOI: 10.1016/J.Jconrel.2010.05.034 |
0.83 |
|
| 2010 |
Wu J, Paudel KS, Strasinger C, Hammell D, Stinchcomb AL, Hinds BJ. Programmable transdermal drug delivery of nicotine using carbon nanotube membranes Proceedings of the National Academy of Sciences of the United States of America. 107: 11698-11702. PMID 20547880 DOI: 10.1073/Pnas.1004714107 |
0.821 |
|
| 2010 |
Paudel KS, Hammell DC, Agu RU, Valiveti S, Stinchcomb AL. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Development and Industrial Pharmacy. 36: 1088-97. PMID 20545522 DOI: 10.3109/03639041003657295 |
0.379 |
|
| 2010 |
Yerramreddy TR, Milewski M, Penthala NR, Stinchcomb AL, Crooks PA. Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery. Bioorganic & Medicinal Chemistry Letters. 20: 3280-3. PMID 20451376 DOI: 10.1016/J.Bmcl.2010.04.049 |
0.712 |
|
| 2010 |
Milewski M, Brogden NK, Stinchcomb AL. Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin. Expert Opinion On Drug Delivery. 7: 617-29. PMID 20205604 DOI: 10.1517/17425241003663228 |
0.847 |
|
| 2010 |
Banks SL, Pinninti RR, Gill HS, Paudel KS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs Journal of Pharmaceutical Sciences. 99: 3072-3080. PMID 20166200 DOI: 10.1002/Jps.22083 |
0.835 |
|
| 2010 |
Majumder M, Stinchcomb A, Hinds BJ. Towards mimicking natural protein channels with aligned carbon nanotube membranes for active drug delivery Life Sciences. 86: 563-568. PMID 19383500 DOI: 10.1016/J.Lfs.2009.04.006 |
0.3 |
|
| 2009 |
Strasinger CL, Scheff NN, Wu J, Hinds BJ, Stinchcomb AL. Carbon Nanotube Membranes for use in the Transdermal Treatment of Nicotine Addiction and Opioid Withdrawal Symptoms. Substance Abuse : Research and Treatment. 3: 31-39. PMID 20582253 DOI: 10.4137/Sart.S1050 |
0.815 |
|
| 2009 |
Chen J, Hammell DC, Spry M, D'Orazio JA, Stinchcomb AL. In vitro skin diffusion study of pure forskolin versus a forskolin-containing Plectranthus barbatus root extract. Journal of Natural Products. 72: 769-71. PMID 19281221 DOI: 10.1021/Np800541K |
0.371 |
|
| 2009 |
Vaddi HK, Banks SL, Chen J, Hammell DC, Crooks PA, Stinchcomb AL. Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone. Journal of Pharmaceutical Sciences. 98: 2611-25. PMID 18972573 DOI: 10.1002/Jps.21594 |
0.749 |
|
| 2009 |
Kiptoo PK, Paudel KS, Hammell DC, Pinninti RR, Chen J, Crooks PA, Stinchcomb AL. Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach. Journal of Pharmaceutical Sciences. 98: 583-94. PMID 18623203 DOI: 10.1002/Jps.21463 |
0.792 |
|
| 2008 |
Banks SL, Pinninti RR, Gill HS, Crooks PA, Prausnitz MR, Stinchcomb AL. Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro. Pharmaceutical Research. 25: 1677-85. PMID 18449628 DOI: 10.1007/S11095-008-9578-3 |
0.798 |
|
| 2008 |
Kiptoo PK, Paudel KS, Hammell DC, Hamad MO, Crooks PA, Stinchcomb AL. In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 33: 371-9. PMID 18321686 DOI: 10.1016/J.Ejps.2008.01.006 |
0.743 |
|
| 2008 |
Wermeling DP, Banks SL, Hudson DA, Gill HS, Gupta J, Prausnitz MR, Stinchcomb AL. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proceedings of the National Academy of Sciences of the United States of America. 105: 2058-63. PMID 18250310 DOI: 10.1073/Pnas.0710355105 |
0.831 |
|
| 2008 |
Strasinger CL, Scheff NN, Stinchcomb AL. Prodrugs and codrugs as strategies for improving percutaneous absorption Expert Review of Dermatology. 3: 221-233. DOI: 10.1586/17469872.3.2.221 |
0.846 |
|
| 2007 |
Medendorp JP, Paudel KS, Lodder RA, Stinchcomb AL. Near infrared spectrometry for the quantification of human dermal absorption of econazole nitrate and estradiol. Pharmaceutical Research. 24: 186-93. PMID 17103333 DOI: 10.1007/S11095-006-9140-0 |
0.401 |
|
| 2007 |
Valiveti S, Agu RU, Hammell DC, Paudel KS, Earles DC, Wermeling DP, Stinchcomb AL. Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 65: 247-52. PMID 17014999 DOI: 10.1016/J.Ejpb.2006.08.009 |
0.324 |
|
| 2006 |
Agu RU, Valiveti S, Paudel KS, Klausner M, Hayden PJ, Stinchcomb AL. Permeation of WIN 55,212-2, a potent cannabinoid receptor agonist, across human tracheo-bronchial tissue in vitro and rat nasal epithelium in vivo. The Journal of Pharmacy and Pharmacology. 58: 1459-65. PMID 17132208 DOI: 10.1211/Jpp.58.11.0006 |
0.329 |
|
| 2006 |
Hamad MO, Kiptoo PK, Stinchcomb AL, Crooks PA. Synthesis and hydrolytic behavior of two novel tripartate codrugs of naltrexone and 6beta-naltrexol with hydroxybupropion as potential alcohol abuse and smoking cessation agents. Bioorganic & Medicinal Chemistry. 14: 7051-61. PMID 16798000 DOI: 10.1016/J.Bmc.2006.06.018 |
0.723 |
|
| 2006 |
Kiptoo PK, Hamad MO, Crooks PA, Stinchcomb AL. Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion. Journal of Controlled Release : Official Journal of the Controlled Release Society. 113: 137-45. PMID 16750868 DOI: 10.1016/J.Jconrel.2006.04.003 |
0.789 |
|
| 2006 |
Medendorp J, Yedluri J, Hammell DC, Ji T, Lodder RA, Stinchcomb AL. Near-infrared spectrometry for the quantification of dermal absorption of econazole nitrate and 4-cyanophenol. Pharmaceutical Research. 23: 835-43. PMID 16554957 DOI: 10.1007/S11095-006-9749-Z |
0.426 |
|
| 2005 |
Nalluri BN, Milligan C, Chen J, Crooks PA, Stinchcomb AL. In vitro release studies on matrix type transdermal drug delivery systems of naltrexone and its acetyl prodrug. Drug Development and Industrial Pharmacy. 31: 871-7. PMID 16305998 DOI: 10.1080/03639040500271944 |
0.426 |
|
| 2005 |
Paudel KS, Nalluri BN, Hammell DC, Valiveti S, Kiptoo P, Hamad MO, Crooks PA, Stinchcomb AL. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo. Journal of Pharmaceutical Sciences. 94: 1965-75. PMID 16052561 DOI: 10.1002/Jps.20398 |
0.815 |
|
| 2005 |
Vaddi HK, Hamad MO, Chen J, Banks SL, Crooks PA, Stinchcomb AL. Human skin permeation of branched-chain 3-0-alkyl ester and carbonate prodrugs of naltrexone. Pharmaceutical Research. 22: 758-65. PMID 15906171 DOI: 10.1007/S11095-005-2592-9 |
0.765 |
|
| 2005 |
Hammell DC, Stolarczyk EI, Klausner M, Hamad MO, Crooks PA, Stinchcomb AL. Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalent. Journal of Pharmaceutical Sciences. 94: 828-36. PMID 15736197 DOI: 10.1002/Jps.20238 |
0.503 |
|
| 2005 |
Valiveti S, Hammell DC, Paudel KS, Hamad MO, Crooks PA, Stinchcomb AL. In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. Journal of Controlled Release : Official Journal of the Controlled Release Society. 102: 509-20. PMID 15653167 DOI: 10.1016/J.Jconrel.2004.10.005 |
0.4 |
|
| 2005 |
Stinchcomb AL. Transdermal drug delivery, 2nd Edition, revised and expanded, R.H. Guy, J. Hadgraft (Eds.). Marcel Dekker, New York (2003), 383 pp. Journal of Controlled Release. 104: 234-235. DOI: 10.1016/J.Jconrel.2004.09.032 |
0.374 |
|
| 2004 |
Agu RU, Valiveti S, Earles DC, Klausner M, Hayden PJ, Wermeling DP, Stinchcomb AL. Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats. Endocrine Research. 30: 455-67. PMID 15554361 DOI: 10.1081/Erc-200035957 |
0.323 |
|
| 2004 |
Pillai O, Hamad MO, Crooks PA, Stinchcomb AL. Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone. Pharmaceutical Research. 21: 1146-52. PMID 15290853 DOI: 10.1023/B:Pham.0000033000.03652.73 |
0.419 |
|
| 2004 |
Valiveti S, Hammell DC, Earles DC, Stinchcomb AL. Transdermal delivery of the synthetic cannabinoid WIN 55,212-2: in vitro/in vivo correlation. Pharmaceutical Research. 21: 1137-45. PMID 15290852 DOI: 10.1023/B:Pham.0000032999.31948.2E |
0.372 |
|
| 2004 |
Hammell DC, Hamad M, Vaddi HK, Crooks PA, Stinchcomb AL. A duplex "Gemini" prodrug of naltrexone for transdermal delivery. Journal of Controlled Release : Official Journal of the Controlled Release Society. 97: 283-90. PMID 15196755 DOI: 10.1016/J.Jconrel.2004.03.020 |
0.588 |
|
| 2004 |
Valiveti S, Kiptoo PK, Hammell DC, Stinchcomb AL. Transdermal permeation of WIN 55,212-2 and CP 55,940 in human skin in vitro. International Journal of Pharmaceutics. 278: 173-80. PMID 15158959 DOI: 10.1016/J.Ijpharm.2004.03.009 |
0.821 |
|
| 2004 |
Valiveti S, Hammell DC, Earles DC, Stinchcomb AL. In vitro/in vivo correlation studies for transdermal delta 8-THC development. Journal of Pharmaceutical Sciences. 93: 1154-64. PMID 15067692 DOI: 10.1002/Jps.20036 |
0.507 |
|
| 2004 |
Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR. Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol. The Journal of Pharmacy and Pharmacology. 56: 291-7. PMID 15025853 DOI: 10.1211/0022357022791 |
0.512 |
|
| 2003 |
Stinchcomb AL. Xenobiotic bioconversion in human epidermis models. Pharmaceutical Research. 20: 1113-8. PMID 12948006 DOI: 10.1023/A:1025024309223 |
0.502 |
|
| 2002 |
Stinchcomb AL, Swaan PW, Ekabo O, Harris KK, Browe J, Hammell DC, Cooperman TA, Pearsall M. Straight-chain naltrexone ester prodrugs: diffusion and concurrent esterase biotransformation in human skin. Journal of Pharmaceutical Sciences. 91: 2571-8. PMID 12434400 DOI: 10.1002/Jps.10239 |
0.595 |
|
| 2002 |
Challapalli PV, Stinchcomb AL. In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation. International Journal of Pharmaceutics. 241: 329-39. PMID 12100860 DOI: 10.1016/S0378-5173(02)00262-4 |
0.478 |
|
| 2002 |
Reddy MB, Stinchcomb AL, Guy RH, Bunge AL. Determining dermal absorption parameters in vivo from tape strip data. Pharmaceutical Research. 19: 292-8. PMID 11934236 DOI: 10.1023/A:1014443001802 |
0.394 |
|
| 1999 |
Stinchcomb AL, Pirot F, Touraille GD, Bunge AL, Guy RH. Chemical uptake into human stratum corneum in vivo from volatile and non-volatile solvents. Pharmaceutical Research. 16: 1288-1293. PMID 10468033 DOI: 10.1023/A:1014866001386 |
0.303 |
|
| 1997 |
Pirot F, Kalia YN, Stinchcomb AL, Keating G, Bunge A, Guy RH. Characterization of the permeability barrier of human skin in vivo Proceedings of the National Academy of Sciences of the United States of America. 94: 1562-1567. PMID 9037093 DOI: 10.1073/Pnas.94.4.1562 |
0.484 |
|
| 1996 |
Stinchcomb AL, Paliwal A, Dua R, Imoto H, Woodard RW, Flynn GL. Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin. Pharmaceutical Research. 13: 1519-23. PMID 8899844 DOI: 10.1023/A:1016079513007 |
0.711 |
|
| 1996 |
Imoto H, Zhou Z, Stinchcomb AL, Flynn GL. Transdermal prodrug concepts: Permeation of buprenorphine and its alkyl esters through hairless mouse skin and influence of vehicles Biological and Pharmaceutical Bulletin. 19: 263-267. PMID 8850319 DOI: 10.1248/Bpb.19.263 |
0.721 |
|
| 1995 |
Stinchcomb AL, Dua R, Paliwal A, Woodard RW, Flynn GL. A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharmaceutical Research. 12: 1526-9. PMID 8584493 DOI: 10.1023/A:1016299824162 |
0.532 |
|
| Show low-probability matches. |
